Cargando…
The Metabolic Bone Disease X-linked Hypophosphatemia: Case Presentation, Pathophysiology and Pharmacology
The authors present a stereotypical case presentation of X-linked hypophosphatemia (XLH) and provide a review of the pathophysiology and related pharmacology of this condition, primarily focusing on the FDA-approved medication burosumab. XLH is a renal phosphate wasting disorder caused by loss of fu...
Autores principales: | Vincze, Jon, Skinner, Brian W., Tucker, Katherine A., Conaway, Kory A., Lowery, Jonathan W., Hum, Julia M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232744/ https://www.ncbi.nlm.nih.gov/pubmed/34203792 http://dx.doi.org/10.3390/life11060563 |
Ejemplares similares
-
Enthesopathy, Osteoarthritis, and Mobility in X-linked Hypophosphatemia
por: Imel, Erik A
Publicado: (2020) -
Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
por: Lyseng-Williamson, Katherine A.
Publicado: (2018) -
Burosumab and Dental Abscesses in Children With X‐Linked Hypophosphatemia
por: Gadion, Margaux, et al.
Publicado: (2022) -
Dental management of patients with X-linked hypophosphatemia
por: Lee, Bin-Na, et al.
Publicado: (2017) -
Growth Curves for Children with X-linked Hypophosphatemia
por: Mao, Meng, et al.
Publicado: (2020)